This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Would you like to diversify but also defer paying big capital gains taxes? And find the entire musical playlist of At the Money on Spotify Some investors have big, concentrated equity positions that have accrued big gains. Perhaps they have some founder stock from a startup. Maybe it’s due to employee stock option plans.
As a Solo GP, one of the only reasons that I’m able to manage over 500 LP investors and 150 portfolio companies is because of AngelList’s software, alongside best-in-class service, that provides back-office support including legal, tax, banking, and regulatory compliance. The next frontier? Regulatory reform.
The space is still relatively nascent, terminology is still enigmatic at times, and there remains a large degree of uncertainly and opaqueness with regulatory and tax compliance, which hinders broader institutional adoption. .
Similarly, I just got a pitch for a startup providing telehealth access that specialized in allergies—which I was pretty excited about until they told me that pharmaceutical companies were fronting the cost of their marketing. I was both horrified and yet not surprised at all.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content